论文部分内容阅读
目的 探讨乌比美克的免疫调节作用。方法 乌比美克临床随机对照试验。结果 在 AML患者中 ,实验组的 CR期、生存期明显长于对照组 (平均 35 6 .6 5天和 44 4.6 3天 VS2 95 .5 9和 378.95天 ) ,实验组的中、重度感染率低于对照组。在 CML患者中 ,实验组的 CR率、CR期和慢性期均高于或长于对照组 (98.18%、35 2 .95天和 5 14天 VS6 0 %、2 46 .34天和 42 1.5 5天 ,P<0 .0 5 ) ,实验组的感染率、感染频度、轻度感染率和抗生素使用时间均低于对照组。两组细胞遗传学改变无显著性差异。 AML和 CML患者中 ,免疫综合疗效实验组均高于对照组。结论 乌比美克对 AML和 CML的治疗有一定疗效
Objective To investigate the immunomodulatory effects of Ubiquinol. Methods Ubimax clinical randomized controlled trials. Results In patients with AML, the experimental group had a significantly longer CR period and longer survival than the control group (mean 35 6 .65 days and 44 4.6 3 days vs. 99.59.59 and 378.95 days). The moderate and severe infection rate was low in the experimental group. In the control group. In CML patients, the CR rate, CR phase, and chronic phase of the experimental group were all higher or longer than the control group (98.18%, 35 2.95 days, and 514 days vs. 60%, 2.46.34 days, and 421.5 days. (P<0.05), the infection rate, frequency of infection, mild infection rate and antibiotic use time were lower in the experimental group than in the control group. There was no significant difference in cytogenetic changes between the two groups. In patients with AML and CML, the immunological comprehensive efficacy in the experimental group was higher than that in the control group. Conclusion Ubiquinol has a certain effect on the treatment of AML and CML